Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients

Journal of Neuro-Oncology

Volumn 130, Issue 3, 2016, Pages 439-448

  Aaberg Jessen, Charlotte ^a   Halle, Bo ^a   Jensen, Stine S ^a   Müller, Sven ^c   Rømer, Unni Maria ^b   Pedersen, Christian B ^a   Brünner, Nils ^b   Kristensen, Bjarne W ^a,d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Dako   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Fluorescence in situ hybridization; Glioblastoma; Glioma; Immunohistochemistry; Plasma; TIMP 1

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; TIMP 1 GENE; TUMOR BIOPSY; BLOOD; BRAIN TUMOR; COPY NUMBER VARIATION; DENMARK; GENETICS; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COHORT STUDIES; DENMARK; DNA COPY NUMBER VARIATIONS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84987621271     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2252-4     Document Type: Article

References (42)

1. Louis DN, Cavenee WK (2007) WHO classification of tumors of the central nervous system. (4th edn). International Agency for Research on Cancer (IARC), Lyon
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/S1470-2045(09)70025-7
3. Aaberg-Jessen C, Christensen K, Offenberg H, Bartels A, Dreehsen T, Hansen S, Schroder HD, Brunner N, Kristensen BW (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95(1):117–128. doi:10.1007/s11060-009-9910-8
4. Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS, Christensen IJ, Brunner N, Kronborg O (2004) Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer 40(14):2159–2164. doi:10.1016/j.ejca.2004.06.011
5. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ (2000) Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 45(1):114–121
6. Kuvaja P, Wurtz SO, Talvensaari-Mattila A, Brunner N, Paakko P, Turpeenniemi-Hujanen T (2007) High serum TIMP-1 correlates with poor prognosis in breast carcinoma—a validation study. Cancer Biomark 3(6):293–300
7. Nielsen HJ, Brunner N, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, Hoyer U, Laurberg S, Stieber P, Blankenstein MA, Davis G, Dowell BL, Christensen IJ (2011) Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol 46(1):60–69. doi:10.3109/00365521.2010.513060
8. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A (2011) Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer 117(3):517–525. doi:10.1002/cncr.25394
9. Rauvala M, Puistola U, Turpeenniemi-Hujanen T (2005) Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99(3):656–663. doi:10.1016/j.ygyno.2005.07.009
10. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10(7):2289–2298
11. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122(9):2050–2056. doi:10.1002/ijc.23337
12. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Miyagi Y (2006) Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer 9(2):106–113. doi:10.1007/s10120-006-0362-y
13. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW (1999) Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80(3–4):495–503. doi:10.1038/sj.bjc.6690384
14. Sorensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brunner N, Usher PA (2006) Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 54(10):1075–1086. doi:10.1369/jhc.5A6896.2006
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235. doi:10.1007/s10549-006-9242-8
16. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14(2):121–130
17. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104(4):542–550. doi:10.3171/jns.2006.104.4.542
18. Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A (2006) HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol 14(2):132–137. doi:10.1097/01.pai.0000150516.75567.13
19. Engel RH, Kaklamani VG (2007) HER2-positive breast cancer: current and future treatment strategies. Drugs 67(9):1329–1341
20. Hicks DG, Tubbs RR (2005) Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36(3):250–261. doi:10.1016/j.humpath.2004.11.010
21. Dong Z, Pang JS, Ng MH, Poon WS, Zhou L, Ng HK (2004) Identification of two contiguous minimally deleted regions on chromosome 1p36.31–p36.32 in oligodendroglial tumours. Br J Cancer 91(6):1105–1111. doi:10.1038/sj.bjc.6602093
22. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158(4):1253–1262. doi:10.1016/s0002-9440(10)64076-x
23. Woehrer A, Sander P, Haberler C, Kern S, Maier H, Preusser M, Hartmann C, Kros JM, Hainfellner JA (2011) FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice—a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol 30(2):47–55
24. Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatric Oncol 37(6):492–504
25. Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB (2008) New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat 112(3):453–459. doi:10.1007/s10549-007-9887-y
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145. doi:10.1200/jco.2006.09.2775
27. Birgisson H, Nielsen HJ, Christensen IJ, Glimelius B, Brunner N (2010) Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer 46(18):3323–3331. doi:10.1016/j.ejca.2010.06.009
28. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17(4):805–816. doi:10.1158/1078-0432.ccr-10-0248
29. Caspersen MB, Sorensen NM, Schrohl AS, Iversen P, Nielsen HJ, Brunner N (2007) Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 22(2):89–94
30. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, Pearson A, Bell BA, Zacharoulis S, Papadopoulos MC (2011) Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro-Oncol 13(1):99–108. doi:10.1093/neuonc/noq170
31. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23(1):42–47
32. Holten-Andersen L, Christensen IJ, Jensen SB, Reibel J, Laurberg S, Nauntofte B, Brunner N, Nielsen HJ (2012) Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study. Scand J Gastroenterol 47(10):1234–1241. doi:10.3109/00365521.2012.711855
33. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brunner N (2000) High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6(11):4292–4299
34. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17(8):2417–2425. doi:10.1158/1078-0432.ccr-10-2402
35. Lee JH, Choi JW, Kim YS (2011) Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. J Gastrointestin Liver Dis 20(3):287–291
36. Lee JH, Choi JW, Kim YS (2011) Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: a meta-analysis. Arch Med Res 42(6):463–468. doi:10.1016/j.arcmed.2011.09.006
37. Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N (2008) A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumour Biol 29(3):181–187. doi:10.1159/000146863
38. Cecchi M, Vaiani M, Ceroti M, Banfi R (2013) A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma. Int J Clin Pharm 35(3):483–487. doi:10.1007/s11096-013-9765-0
39. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. doi:10.1200/jco.2008.16.3055
40. Moller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U (2012) A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol 51(6):797–804. doi:10.3109/0284186x.2012.681063
41. Ruiz-Sanchez D, Calero MA, Sastre-Heres AJ, Garcia MT, Hernandez MA, Martinez FM, Pena-Diaz J (2012) Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen. Oncology Letter 4(5):1114–1118. doi:10.3892/ol.2012.861
42. Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, Glimelius B (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13(14):4117–4122. doi:10.1158/1078-0432.ccr-07-0186